monoamine oxidase inhibitor

(redirected from MAO inhibitor)
Also found in: Dictionary, Thesaurus, Medical.
Related to MAO inhibitor: Ritalin, SSRI, serotonin, COMT inhibitor, MAOI inhibitor

monoamine oxidase inhibitor

[män·ō′am‚ēn ′äk·sə‚dās in′hib·əd·ər]
(pharmacology)
Any drug, such as isocarboxazid and tranylcypromine, that inhibits monoamine oxidase and thereby leads to an accumulation of the amines on which the enzyme normally acts.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
A few irreversible or non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine) are associated strongly with instances of severe serotonin syndrome, but a large number of opiates, analgesics, tricyclic antidepressants, selective serotonin reuptake inhibitors and antimigraine agents have also been implicated.
It is probable that one of the leading causes of protracted depressive states may be an autoimmune process, and specifically, the formation of auto-antibodies to the endogenous MAO inhibitor isatin or isatin containing tribuline.
Food interacting with MAO inhibitors. Med Lett Drugs Ther 1989; 31:11--2.
MAO inhibitors like Parnate block the enzyme monoarnine oxidase, which breaks down serotonin and norepinephrine.
The selegiline patch would be the first transdermal medication approved to treat depression, and the 20-mg formulation would be the first MAO inhibitor approved for treating depression without dietary tyramine restrictions.
The approval marks another first: The lowest dose--the 20-mg patch that delivers 6 mg of selegiline over 24 hours--does not require dietary tyramine restrictions, making this the first MAO inhibitor approved for treating depression without such a restriction.
Conventional MAO inhibitors interfere with the action of an isoenzyme, MAO-A, that normally prevents the absorption of tyramine, a food component that can raise blood pressure dramatically, he said.
At oral doses that achieve an antidepressant effect, however, selegiline loses its selectivity, inhibiting both MAO-A and MAO-B and arousing the same safety issues as with other MAO inhibitors.
It also has MAO inhibitor activity, but not to a clinically significant degree.
On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.
"There is good data behind MAO inhibitors, and there is increasingly good data behind [selective norepinephrine reuptake inhibitors]," he said.
Browse 66 Market Data Tables and 33 Figures spread through 113 Pages and in-depth TOC on "Parkinson's Disease Treatment Market" http://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html Early buyers will receive 10% customization on this report By drug class, the carbidopa/levodopa segment is estimated to dominate the market in 2017 On the basis of drug class, the Parkinson's disease therapeutic drugs market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other drugs.